secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0000950170-23-066458
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis enters commercialization agreement with Tempus Labs for NeXT Personal Dx assay
--------------------------------------------------------------------------------

- Tempus will pay Personalis up to $12,000,000 in Market Development Fee, including a $3M activation fee.
- Personalis issued two warrants to Tempus to purchase up to 4,609,400 shares each at $1.50 and $2.50 per share.
- Tempus will market Personalis' NeXT Personal Dx assay for breast cancer, lung cancer, and immuno-oncology monitoring.
- The agreement has a five-year term with exclusivity until December 31, 2027, and includes milestones for up to $12M in fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000095017023066458/0000950170-23-066458-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000095017023066458/psnl-20231125.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-066458

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer